Lennart Kühl

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lennart Kühl, Annelie K Schäfer, Sebastian Kraft, Nadine Beha, Roland E Kontermann, Oliver Seifert
eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs 15 (1) (2023)
Lennart Kühl, Annelie K Schäfer, Sebastian Kraft, Nadine Beha, Roland E Kontermann, Oliver Seifert
eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs 15 (1) (2023)
Lennart Kühl, Annelie K Schäfer, Sebastian Kraft, Nadine Beha, Roland E Kontermann, Oliver Seifert
eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs 15 (1) (2023)
Lennart Kühl, Annelie K Schäfer, Sebastian Kraft, Nadine Beha, Roland E Kontermann, Oliver Seifert
eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs 15 (1) (2023)
Lennart Kühl, Nadine Beha, Roland E Kontermann, Oliver Seifert
The eIg technology to generate Ig-like bispecific antibodies. mAbs 14 (1) (2022)
Alexander Rau, Nicole Janssen, Lennart Kühl, Thomas Sell, Svetlana Kalmykova, Thomas E Mürdter, Marc-H Dahlke, Christine Sers, Markus Morkel, Matthias Schwab, Roland E Kontermann, Monilola A Olayioye
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. Molecular cancer therapeutics 21 (5) (2022)
Nadine Beha, Katharina Kocher, Martin Siegemund, Martina S Lutz, Lennart Kühl, Oliver Seifert, Roland E Kontermann
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). Oncoimmunology 11 (1) (2022)
Alexander Rau, Katharina Kocher, Mirjam Rommel, Lennart Kühl, Maximilian Albrecht, Hannes Gotthard, Nadine Beha, Bettina Noll, Monilola A Olayioye, Roland E Kontermann, Oliver Seifert
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. mAbs 13 (1) (2022)